Cowen analyst Marc Frahm raised the firm’s price target on Incyte to $100 from $95 and keeps an Outperform rating on the shares. The analyst said they reported strong Opzelura revenue growth that was driven by strong volume and net pricing gains and given strong physician feedback, we expect these trends to continue
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCY:
- Incyte reports Q4 EPS 62c, consensus 58c
- Incyte initiated with an Overweight at Piper Sandler
- Incyte’s novel mutant CALR antibody unveiled at ASH 2022
Questions or Comments about the article? Write to editor@tipranks.com